The firm said that it has completed clinical trials for the Group B Strep assay for the FDA and will start trials for the C. difficile test this month.
The test is the third in the firm's line of infectious disease assays, which also includes tests for meningococcus and Group B Strep.
The company said it expects a 1 percent increase in 2016 revenues, but noted that the results were adversely affected by certain competitive pressures in Q4, among other problems.
Nearly 8,000 patients participated in a screening study that used a PCR-based detection assay from Becton Dickinson, uncovering a 5 percent carrier rate.
A draft guidance issued by the US Food and Drug Administration regarding fecal microbiota transplants may affect how stool banks operate.
At the Personalized Medicine World Conference, researchers talked about how understanding the microbiome is leading to therapies aimed at keeping it healthy.
The company plans to add assays for Group B Streptococcus, Clostridium difficile, and norovirus in 2016 to complement its existing meningitis test.
Wells Fargo downgraded Cepheid from Outperform to Market Perform, citing the firm's "credibility and visibility" following a revised 2017 outlook.
The Quebec City, Canada-based firm will launch its point-of-care molecular platform with GBS and C. diff tests next year as CE-IVD products.
The Austin, Texas-based molecular diagnostics firm logged $60.6 million in Q3 revenues as its system sales shot up 26 percent to $9.6 million.
The Centers for Disease Control and Prevention estimates more people get sick and die from drug-resistant germs than previously thought, the Washington Post reports.
According to the Associated Press, three universities and a healthcare institution are sharing a gift of $1 billion.
New rules seek to limit the type of scientific and medical research that can be used to guide public health regulations, the New York Times reports.
In Nature this week: FreeHi-C approach simulates Hi-C data from interacting genome fragments, and more.